Advanced tools, insights and data to navigate the markets.
Advanced tools, insights and data to navigate the markets.
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Danimer Scientific, Inc.
The "Laboratory Proficiency Testing - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
Fisker Inc. announced a partnership with Onto, the UK-based all-inclusive electric car subscription service for private and business users.
Maxwell Biosciences, a preclinical biotechnology platform company, today announced that it has branded its patented biostable peptide analogs, which comprise small, synthetic oligomers ("peptoids") which preclinical studies have shown function as biostable mimics of the powerful cathelicidin peptide—the human body’s primary line of innate immune defense against rapidly evolving viruses.
BGR vs LSH Dream11 Prediction, Fantasy Cricket Tips, Playing XI, Pitch Report, Dream11 Team, and Injury Update of Dream11 Vincy Premier League T10 match between La Soufriere Hikers and Botanical Garden Rangers. The first match of Tuesday’s doubleheader will be played between the two teams which are at the polar end of the points table i.e La Soufriere Hikers and Botanical Garden Rangers will lock horns against each other in the 7th match of the Dream11 Vincy Premier League T10 tournament. BGR vs LSH Dream11 Vincy Premier League T10 Match 7 Details: The 7th match of Dream11 Vincy Premier League The post BGR vs LSH Dream11 Prediction, Fantasy Cricket Tips, Playing XI, Pitch Report, Dream11 Team and Injury Update – Dream11 Vincy Premier League T10 appeared first on CricketAddictor.
Acquisition to Transform and Strengthen Guardion’s Clinical Nutrition Product Portfolio Guardion Will Continue to Explore Additional Growth Opportunities to Further Expand its Presence in the Clinical Nutrition Market SAN DIEGO, May 18, 2021 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a clinical nutrition and diagnostics company that develops clinically supported nutrition, medical foods, supplements and medical devices, today announced the first acquisition being effected under its recently-appointed CEO’s new growth strategy to more widely compete in the clinical nutrition market. The Company has entered into an Equity Purchase Agreement with Adare Pharmaceuticals, Inc. (“Adare”) to acquire all of the equity of Activ Nutritional, LLC for a cash payment of $26 million, subject to certain adjustments. The transaction is subject to several customary closing conditions and is expected to close by June 30, 2021. Adare owns the Viactiv® line of supplement chews for bone health, immune health and other applications. Currently marketed through many of the nation’s largest retailers, including, among others, Walmart (retail and online), Target and Amazon, the Viactiv product lines are expected to become Guardion’s most prominent product lines, as well as to provide access to significant opportunities in the short-term for growth and expansion. Bret Scholtes, Guardion’s CEO commented, “The Activ Nutritional acquisition satisfies a number of our current objectives as we continue efforts to build our position within the clinical nutrition market. Activ Nutritional has an established brand and presence from which we can significantly expand our capabilities in terms of marketing, product lines and new distribution channels. It also will provide a significant boost to our current revenues and operating earnings. The transaction immediately expands our reach beyond ocular health, which has long been our primary focus, and allows us to more easily explore opportunities in the wider world of clinical nutrition. It also positions us to more adeptly identify additional opportunities to expand our presence in the market, whether through improved commercialization of our current products and product pipeline or through other acquisitions and other strategic transactions. We look forward to announcing to our shareholders the closing of this important transaction.” Sheppard, Mullin, Richter & Hampton LLP is serving as Guardion’s legal advisor. Corporate Finance Associates served as Guardion’s financial advisor. Stout provided due diligence analysis and support. The Company will be filing a Current Report on Form 8-K with the U. S. Securities and Exchange Commission (the “SEC”) to provide additional information on this transaction. About Guardion Health Sciences, Inc. Guardion Health Sciences, Inc. (Nasdaq: GHSI), is a clinical nutrition and diagnostics company. Guardion offers a portfolio of science-based, clinically supported nutrition, medical foods, supplements, and diagnostic products that support healthcare professionals, their patients, and consumers in achieving health goals. Guardion’s commercial and developmental initiatives are supported by equally impressive scientific and medical advisory boards, led by seasoned business executives and physicians with many years of experience. Information and risk factors with respect to Guardion and its business, including its ability to successfully develop and commercialize its proprietary products and technologies, may be obtained in the Company’s filings with the SEC at www.sec.gov. Forward-Looking Statement Disclaimer With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements involve unknown risks and uncertainties that may individually or materially impact the matters discussed herein for a variety of reasons that are outside the control of the Company, including, but are not limited to, the Company’s ability to raise sufficient financing to implement its business plan, the integration of a new management team, the integration of one or more acquisition targets, the impact of the COVID-19 pandemic on the Company’s business, operations and the economy in general, the Company’s ability to successfully develop and commercialize its proprietary products and technologies, and the Company’s ability to maintain compliance with Nasdaq’s listing requirements. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Relations Contact:CORE IRScott Arnold516email@example.com Media Relations Contact:Jules AbrahamDirector of Public RelationsCORE IR917firstname.lastname@example.org
TORONTO, May 18, 2021 (GLOBE NEWSWIRE) -- Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (FRA:20MP) is pleased to announce it has received its third-party Bio Safety Level 4 (“BSL-4”) lab study results from its recent COVID-19 viral clearance study conducted with its solubilized Ivermectin technology - Ivectosol™. Study Results A single dose of 2.5 milligrams per kilogram of Ivectosol™ was effective at interfering with viral replication and driving viral clearance of the B.1.1.7 COVID-19 variant.Tests done in vitro showed the same antiviral effect at 5uM Ivectosol™ concentration after 24 hours and again after 48 hours against all three COVID-19 variants tested - the original B.1.1.7 variant, the South African B.1.351 variant, and the P.1 Brazil variant. “This is the validation of our Ivectosol™ technology that we were looking for in its direct application to stop the replication of the targeted COVID-19 variants,” stated Dennis Hancock, President and CEO of Mountain Valley MD. “Knowing that Ivectosol™ has viral clearance effect on the three targeted variants we tested in the strictest lab environment in the world provides us with the confidence to pursue immediate human applications. We plan to progress quickly into phase one human trials to support our vision for broad adoption and to also provide necessary and urgent support for the most disadvantaged communities globally.” The BSL-4 study was the first of its kind ever conducted with human grade solubilized Ivermectin anywhere in the world. This was also the world’s first to study to conduct in vitro replication on all three COVID-19 variants studied. The study was conducted in a Bio Safety Level 4 facility where laboratories are designed for diagnostic work and research on easily acquired respiratory viruses that can often cause severe or fatal disease. To assess the Company’s Ivectosol™ performance, transgenic mice were modified with human ACE2 receptors and then dosed by aerosolization with COVID-19. After five days, the subject mice were dosed with ascending therapeutic doses of Ivectosol™ as intramuscular injection. The Company will immediately pursue a combined pharmacokinetic and phase one human trial to verify the efficacy of Ivectosol™ sublingual wafers in COVID-19 infected patients. The new human studies are anticipated to include the “triple-mutant India variant” B.1.617, and will determine overall efficacy, speed of viral clearance and safety levels of the Ivermectin drug in the Company’s Ivectosol™ formulation. The study design was led by the Company’s key scientific advisor, Dr. John Clements. Dr. Clements is Emeritus Professor of Microbiology and Immunology at Tulane University School of Medicine and has over 35 years of experience in vaccine, immunology and infectious diseases research and development, with a distinguished scientific career focused on developing and evaluating vaccines for a wide range of infectious diseases globally. The Company’s previously completed pre-clinical trial work with a third-party Contract Research Organization tested solubilized Ivermectin via both an intramuscular injection and applied to rapid dissolve oral strips with the Company’s patented Quicksome™ desiccated liposome technology compared to existing oral and subcutaneous injection solutions. The results demonstrated that the Company’s patented Quicksol™ solubilized Ivermectin offered superior pharmacokinetic performance across every single measure conducted, with no adverse side effects using up to 1/8th of the Ivermectin drug – a critical component that enables applications to use less of the Ivermectin drug while driving faster viral clearance. “Consistent with MVMD’s previous pre-clinical trials on dose sparing, we can now pursue a meaningful reduction in the required Active Pharmaceutical Ingredient (API) Ivermectin in human applications with consistent effect,” stated Mike Farber, Director of Life Sciences. “Using less of the Ivermectin drug and enabling its delivery in novel rapid dissolve sublingual tablets and human injectable forms offers significant advantages in cost and efficacy. Even eliminating the need for water for consumption of MVMD’s sublingual Ivectosol™ we believe will be an important element in targeted third world countries where water supply can be as equally difficult to access as compared to expensive vaccines.” MVMD’s solubility technology applied to the Ivermectin drug is the only form in the world that uses strictly excipients that are currently approved by the US Food and Drug Administration (FDA), making it a leading candidate for human injection and sublingual applications as well as significantly broader husbandry and companion animal treatments based on its low viscosity. The Company is not making any express or implied claims that its technology or product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time. ABOUT MOUNTAIN VALLEY MD HOLDINGS INCMountain Valley MD is building a world-class biotech and life sciences company organization centred around the implementation of its patented Quicksome™ oral drug formulation and delivery technologies and its Quicksol™ solubilization technology for macrocyclic lactones, to innovate industry leading products that are sought out globally. MVMD’s proposition for delivering Quicksome™ formulations that have rapid onset, high bioavailability, low variability and precision dosing is core to the Company’s success across key health and wellness categories. Consistent with its vision towards “Helping People Live Their Best Life”, MVMD applies its Quicksome™ and Quicksol™ technologies to its ground-breaking work for advanced delivery of vaccines and pharmaceutical drugs as well as the development of products for pain management, weight loss, energy, focus, sleep, anxiety, and more. The Company’s patented Quicksome™ desiccation technology utilizes advanced liposomes and other stabilizing molecules to encapsulate and formulate active ingredients into highly efficient product formats that are consumed orally. The result is a new generation of product formulations that are capable of delivering vaccines, drugs and nutraceuticals into the body faster, with greater impact, efficiency and accuracy. The Company’s patented Quicksol™ solubilization technology covers all highly solubilized macrocyclic lactones (including the drugs Ivermectin and Selamectin). MVMD’s solubility technology applied to the Ivermectin drug is the only form in the world that only uses excipients that are currently approved by the US Food and Drug Administration (FDA), making it a leading candidate for human injection and sublingual applications as well as significantly broader husbandry and companion animal treatments based on its low viscosity. For more Company information and contact details, visit www.mountainvalleymd.com. SOURCE: Mountain Valley MD Holdings Inc. CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION Certain statements contained in this news release may constitute forward-looking information. Forward-looking information is often, but not always, identified by the use of words such as "anticipate", "plan", "estimate", "expect", "may", "will", "intend", "should", and similar expressions. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information. The Company's actual results could differ materially from those anticipated in this forward-looking information as a result of regulatory decisions, competitive factors in the industries in which the Company operates, prevailing economic conditions, and other factors, many of which are beyond the control of the Company. The Company is making forward-looking statements, including but not limited to its forthcoming phase I human trials, over which outcomes it will have no direct control, and the implications of the acceptance of Ivectosol™ for use in the treatment of COVID-19, including variants, or otherwise. The Company believes that the expectations reflected in the forward-looking information are reasonable, but no assurance can be given that these expectations will prove to be correct and such forward-looking information should not be unduly relied upon. Any forward-looking information contained in this news release represents the Company's expectations as of the date hereof and is subject to change after such date. The Company disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable securities legislation. CONTACT: For further information: Dennis Hancock President and Chief Executive Officer Mountain Valley MD Holdings Inc. Telephone: 647-725-9755 Email: email@example.com www.mountainvalleymd.com
Skin Packaging Market Research Report by Type (Carded Skin Packaging and Non-Carded Skin Packaging), by Base Material (Paper & Paperboard and Plastic Films), by Heat Seal Coating, by Application - Global Forecast to 2025 - Cumulative Impact of COVID-19New York, May 18, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Skin Packaging Market Research Report by Type, by Base Material, by Heat Seal Coating, by Application - Global Forecast to 2025 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p05911496/?utm_source=GNW Market Statistics:The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.1. The Global Skin Packaging Market is expected to grow from USD 9,765.29 Million in 2020 to USD 13,302.70 Million by the end of 2025.2. The Global Skin Packaging Market is expected to grow from EUR 8,562.39 Million in 2020 to EUR 11,664.06 Million by the end of 2025.3. The Global Skin Packaging Market is expected to grow from GBP 7,611.98 Million in 2020 to GBP 10,369.38 Million by the end of 2025.4. The Global Skin Packaging Market is expected to grow from JPY 1,042,204.48 Million in 2020 to JPY 1,419,735.90 Million by the end of 2025.5. The Global Skin Packaging Market is expected to grow from AUD 14,180.50 Million in 2020 to AUD 19,317.29 Million by the end of 2025.Market Segmentation & Coverage:This research report categorizes the Skin Packaging to forecast the revenues and analyze the trends in each of the following sub-markets:Based on Type, the Skin Packaging Market studied across Carded Skin Packaging and Non-Carded Skin Packaging. Based on Base Material, the Skin Packaging Market studied across Paper & Paperboard and Plastic Films. Based on Heat Seal Coating, the Skin Packaging Market studied across Solvent-Based Heat Seal Coating and Water-Based Heat Seal Coating. Based on Application, the Skin Packaging Market studied across Consumer Goods, Food, and Industrial Goods. Based on Geography, the Skin Packaging Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom. Company Usability Profiles:The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Skin Packaging Market including Amcor plc, Bemis Company, Inc., Berry Plastics Group, Inc., Clondalkin Group Holdings B.V., Display Pack Inc., E.I. Du Pont De Nemours and Company, Flexopack S.A., G. Mondini SPA, Impressions, IPS Packaging & Automation, LD Packaging Co ., LTD, Linpac Packaging Limited, Plastopil Europe B.V., Pro Vision Packaging (China) co., Ltd, Rohrer Corporation, Sealed Air Corporation, Shanghai Sanjing Machinery Co., Ltd, The DOW Chemical Company, and Westrock Company. Cumulative Impact of COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.FPNV Positioning Matrix:The FPNV Positioning Matrix evaluates and categorizes the vendors in the Skin Packaging Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.Competitive Strategic Window:The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on the market offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developmentsThe report answers questions such as:1. What is the market size and forecast of the Global Skin Packaging Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global Skin Packaging Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Skin Packaging Market?4. What is the competitive strategic window for opportunities in the Global Skin Packaging Market?5. What are the technology trends and regulatory frameworks in the Global Skin Packaging Market?6. What are the modes and strategic moves considered suitable for entering the Global Skin Packaging Market?Read the full report: https://www.reportlinker.com/p05911496/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: firstname.lastname@example.org US: (339)-368-6001 Intl: +1 339-368-6001
MONTREAL, May 18, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Levesque, President and Chief Executive Officer will participate in a virtual fireside chat hosted by Edward Nash at Canaccord Genuity on Thursday, May 20, 2021 at 2:00 p.m. ET. The live webcast will be available at https://www.webcaster4.com/Webcast/Page/2332/40747. The live and archived webcast link will also be available in the ‘News’ section of the Company’s website. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR at www.sedar.com and on EDGAR at www.sec.gov. For media inquiries:Denis BoucherVice-President, Communications and Corporate Affairs514-336-7800 For investor inquiries:Leah GibsonSenior Director, Investor Relationsir@theratech.com617-356-1009
'This is a wake-up call.'
The friends were joined by their wives as they reunited in London.
WHITEHALL, Ohio, May 18, 2021 (GLOBE NEWSWIRE) -- Heartland BancCorp (OTCQX: HLAN), today parent company of Heartland Bank, today announced that the bank has once again been named to American Banker magazine’s Top 200 Publicly Traded Community Banks and Thrifts. In its May 2021 issue, American Banker ranked Heartland 82nd on its Top 200 Publicly Traded Community Banks and Thrifts list based on three-year average return on equity (“ROE”) as of 12/31/20 (Source: Capital Performance Group). “We are honored to have made American Banker’s Top 200 list for the thirteenth consecutive year,” said G. Scott McComb, Chairman, President and CEO. “Being listed in the Top 200 is a great affirmation of our extraordinary staff and their commitment to our customers and to the communities we serve.” About Heartland BancCorp Heartland BancCorp is a registered Ohio bank holding company and the parent of Heartland Bank, which operates 18 full-service banking offices and TransCounty Title Agency, LLC. Heartland Bank, founded in 1911, provides full-service commercial, small business, and consumer banking services; professional financial planning services; and other financial products and services. Heartland Bank is a member of the Federal Reserve, a member of the FDIC, and an Equal Housing Lender. Heartland BancCorp is currently quoted on the OTC Markets (OTCQX) under the symbol HLAN. Learn more about Heartland Bank at Heartland.Bank. Contacts: G. Scott McComb, Chairman, President & CEO Heartland BancCorp 614-337-4600
New Delhi, May 18 (PTI) The Vishva Hindu Parishad (VHP) on Tuesday appealed to people to donate for the rehabilitation and welfare of those affected by the post-poll violence in West Bengal.
Children orphaned by COVID, Kejriwal said, will get Rs 2,500 monthly pension till they attain the age of 25 years.
We are proud to announce the 20th anniversary of our firm and our flagship fund, Titan Masters Fund LP. In an industry where change is the norm, we take great satisfaction in the longevity we have been able to sustain. Since launching Titan in 2001 our goal has been to provide our investors with solutions to solve their problems. We have done that historically using alternative investments in the form of comingled funds, seed opportunities, insurance dedicated funds, CLO warehouses, custom funds, ESG funds and most recently our offering of the Titan Inflation Plus Fund to take advantage of a rising inflation environment. Over the years our products have changed with the times but our dedication to our investors has never wavered.
ATHENS, Greece, May 18, 2021 (GLOBE NEWSWIRE) -- Diana Shipping Inc. (NYSE: DSX), (the “Company”), a global shipping company specializing in the ownership of dry bulk vessels, today announced that on May 14, 2021, it signed a sustainability linked loan facility with ABN AMRO Bank N.V., through six wholly-owned subsidiaries (the “Borrowers”), in the amount of US$91 million. The purpose of the senior secured term loan facility was the refinancing of existing indebtedness on the Borrowers' vessels, m/v Medusa, m/v New Orleans, m/v Los Angeles, m/v Philadelphia, m/v Santa Barbara and m/v Artemis, and for general corporate purposes. Commenting on this transaction, the Company’s Chief Executive Officer, Ms. Semiramis Paliou, stated: “We are pleased to have signed this loan agreement with ABN AMRO Bank N.V., which is in accordance with our policy of managing our cash flow and loan maturities proactively for the benefit of our shareholders. The added sustainability aspect is essential not only for the potential additional cost savings, but more importantly because it is in line with the Company’s commitment towards its long-term sustainability goals.” Upon completion of the previously announced sale of one Panamax dry bulk vessel, the m/v Naias, Diana Shipping Inc.’s fleet will consist of 36 dry bulk vessels (4 Newcastlemax, 12 Capesize, 5 Post-Panamax, 5 Kamsarmax and 10 Panamax). As of today, the combined carrying capacity of the Company’s fleet, including the m/v Naias, is approximately 4.7 million dwt with a weighted average age of 10.24 years. A table describing the current Diana Shipping Inc. fleet can be found on the Company’s website, www.dianashippinginc.com. Information contained on the Company’s website does not constitute a part of this press release. About the Company Diana Shipping Inc. is a global provider of shipping transportation services through its ownership of dry bulk vessels. The Company’s vessels are employed primarily on medium to long-term time charters and transport a range of dry bulk cargoes, including such commodities as iron ore, coal, grain and other materials along worldwide shipping routes. Cautionary Statement Regarding Forward-Looking Statements Matters discussed in this press release may constitute forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides safe harbor protections for forward-looking statements in order to encourage companies to provide prospective information about their business. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts. The Company desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbor legislation. The words “believe,” “anticipate,” “intends,” “estimate,” “forecast,” “project,” “plan,” “potential,” “may,” “should,” “expect,” “pending” and similar expressions identify forward-looking statements. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, Company management’s examination of historical operating trends, data contained in the Company’s records and other data available from third parties. Although the Company believes that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies that are difficult or impossible to predict and are beyond the Company’s control, the Company cannot assure you that it will achieve or accomplish these expectations, beliefs or projections. In addition to these important factors, other important factors that, in the Company’s view, could cause actual results to differ materially from those discussed in the forward-looking statements include the severity, magnitude and duration of the COVID-19 pandemic, including impacts of the pandemic and of businesses’ and governments’ responses to the pandemic on our operations, personnel, and on the demand for seaborne transportation of bulk products; the strength of world economies and currencies, general market conditions, including fluctuations in charter rates and vessel values, changes in demand for dry bulk shipping capacity, changes in the Company’s operating expenses, including bunker prices, drydocking and insurance costs, the market for the Company’s vessels, availability of financing and refinancing, changes in governmental rules and regulations or actions taken by regulatory authorities, potential liability from pending or future litigation, general domestic and international political conditions, potential disruption of shipping routes due to accidents or political events, vessel breakdowns and instances of off-hires and other factors. Please see the Company’s filings with the U.S. Securities and Exchange Commission for a more complete discussion of these and other risks and uncertainties. The Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. CONTACT: Corporate Contact: Ioannis Zafirakis Director, Chief Financial Officer, Chief Strategy Officer, Treasurer and Secretary Telephone: + 30-210-9470-100 Email: email@example.com Website: www.dianashippinginc.com Investor and Media Relations: Edward Nebb Comm-Counsellors, LLC Telephone: + 1-203-972-8350 Email: firstname.lastname@example.org
New Dolby Atmos tracks will be added constantly and as many as 75 million songs will be available in Lossless Audio.
Jammu, May 18 (PTI) The BJP, Congress, National Conference and the Jammu and Kashmir Apni Party condoled the demise of former union minister Chaman Lal Gupta here on Tuesday.
Mumbai, May 18 (PTI) Homegrown private equity major True North on Tuesday said it is aspiring to cover a “majority” of its assets under the environmental, social and governance (ESG) principles.
The identity of Zombies, who appeared in last night's WWE WrestleMania Backlash, has been revealed.